Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Eur Urol
; 85(2): e58-e59, 2024 Feb.
Article
in En
| MEDLINE
| ID: mdl-38071169
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Eur Urol
Year:
2024
Document type:
Article